What question did this study set out to answer?

This study aims to compare the effectiveness of two different chemotherapy combinations in treating small-cell lung cancer.

April 15, 1982Cancer

Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lung

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial compares chemotherapy regimens in small-cell lung cancer, indicating potential benefits of treatment switching.

This study aims to compare the effectiveness of two different chemotherapy combinations in treating small-cell lung cancer.
Compared CTX + CCNU with CTX + CCNU + procarbazine in 440 evaluable patients.
Evaluated overall response rates and median survival times for responders and nonresponders.
Assessed outcomes for treatments including ADR, ADR + VCR, and ADR + VP-16 for nonresponders.
Three-drug combination showed a 57% overall response rate compared to 44% for the two-drug combination.
Median survival was 27 weeks with procarbazine and 29 weeks without it.
Responders who switched to cycled therapy after day 42 had a median survival of 38 weeks compared to 29 weeks for those who did not.

Ettinger et al. (1982) studied this question.

View Full Paper

Ask AI

Bookmark